Cancer
Enzon's PEG-SN38 Featured in Clinical Cancer Research
Published in Cancer Weekly, April 1st, 2008
PEG-SN38, a PEGylated form of SN38, utililizes new releasable PEGylation technology developed at Enzon. The technology enabled significantly increased solubility, a longer apparent half-life, higher exposure, and significantly enhanced therapeutic index compared to CPT-11 in several preclinical xenograft models, including models of in vivo CPT-11 resistance.
In an experiment using xenograft models for breast tumors, treatment with PEG-SN38 given below...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-04-01)
More Articles from Cancer Weekly
- Adverse Drug Reactions
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor - Breast Cancer
Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Women's Negative Attitudes Toward Mammograms - Breast Cancer
Review of Data from Eight U.S. Cancer Institutions Supports Use of Hyperthermia with Radiation for Treating Recurrent Breast Cancer - Cancer
'A Journal for Karen': Author Shares Gift of Love for Sister with Readers Everywhere Touched by Cancer - Cancer Gene Therapy
Investigators at Lanzhou University target cancer gene therapy - Cancer Gene Therapy
Research from M. Lakatosovaandelova and colleagues provide new insights into cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
